A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of Subjects with Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE)
|Effective start/end date||11/24/15 → 6/30/19|
- TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.